Skip to content
qps logo

Generic filters
Exact matches only
Search in title
Search in content
Search in excerpt
Contact Us → Apply Now →

  • Home
  • About
    • Staff
    • Safety
    • FAQs
    • Location
    • Blog
  • Studies
    • Available Studies
    • Ongoing Studies
  • Enroll
    • Application
    • Study Process
    • How to Participate
  • Join Our Team
  • Referral Program
  • Contact
qps logo

Generic filters
Exact matches only
Search in title
Search in content
Search in excerpt
Contact Us → Apply Now →

  • Home
  • About
    • Staff
    • Safety
    • FAQs
    • Location
    • Blog
  • Studies
    • Available Studies
    • Ongoing Studies
  • Enroll
    • Application
    • Study Process
    • How to Participate
  • Join Our Team
  • Referral Program
  • Contact

About Clinical Research
Study #53823 – Study is Full

This QPS Missouri Clinical Research study will be evaluating the effects of food on the metabolic and absorption rate of an investigational drug used for the treatment of tumors

Are You a Good Fit?

Men and Women

Healthy

Between 18 and 55 years of age

Non-Smoker/ Non-Nicotine User

BMI (Body Mass Index) between 18 and 32 kg/m2

  • Receive up to $9,000 for your participation in this study
Portraits of happy multiracial people posing on colorful backgrounds

What are the Time Requirements?

This study will consist of a 15-night in-house stay.. Study dates are as follows:
Group 3
Visit Dates
Stay
Thursday, March 13, 2025 - Friday, March 28, 2025

How Much: $9,000

BMI Calculator

BMI Calculator Simple

Weight

Unit of measurement*
cm
kg
ft
in
lbs

BMI

Referral Program

Do not forget our REFERRAL PROGRAM. Earn at least $200 for every new participant you refer who completes a study.*

*No referral bonuses are paid out for outpatient vaccine studies.

All study dates are tentative and subject to change.

We will update the clinical research studies list weekly. Be sure to check with us either by calling or going online. Call (417) 831-2048 or visit 417studies.com for more information. You can also visit the Screening and Recruitment Center located at 2025 W. Sunshine Street, L-109. Office hours are Monday through Friday from 8 a.m. to 5 p.m.

Multiple blood draws are required throughout the duration of this clinical research study

Have received an investigational product or device within 30 days prior to the first study drug administration.

Females of childbearing potential must agree to use highly effective contraceptive methods and avoid egg donation during the study treatment and for at least 184 days after the last dose of RLY-2608. Highly effective contraceptive methods include:
• Double barrier (condom, diaphragm or cervical cap with spermicidal foam, gel or cream) plus one of the following hormonal
methods, used consecutively for at least 3 months prior to first dose of study drug:
o Combined (estrogen and progestogen containing) oral, intravaginal or transdermal hormonal contraception associated with
the inhibition of ovulation
o Progestogen-only oral, injectable or implantable hormonal contraception associated with the inhibition of ovulation
o Intrauterine device
o Intrauterine hormone-releasing system (IUS)
• Vasectomized partner, if the vasectomized partner has received medical assessment of the surgical success
• Sexual abstinence, defined as refraining from heterosexual intercourse

A female is considered to be of child-bearing potential unless she:
• has had a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy;
• has been amenorrhoeic for ≥ 12 months (including no irregular menses or spotting) in the absence of any medication which
induces a menopausal state and has documented ovarian insufficiency by follicle-stimulating hormone levels within the
institutional laboratory postmenopausal range.

Men of reproductive potential agree to use highly effective contraceptive methods and to avoid sperm donation during the study treatment and for 94 days after the last dose. A man is considered to be of child-producing potential unless he has had a bilateral vasectomy with documented aspermia, or a bilateral orchiectomy.
• Double barrier (condom, diaphragm or cervical cap with spermicidal foam, gel or cream) plus one of the following hormonal
methods, used consecutively for at least 3 months prior to first dose of study drug:
• Female partner on combined (estrogen and progestogen containing) oral, intravaginal or transdermal hormonal contraception
associated with the inhibition of ovulation
• Female partner on progestogen-only oral, injectable or implantable hormonal contraception associated with the inhibition of
ovulation
• Female partner with Intrauterine device
• Female partner with Intrauterine hormone-releasing system (IUS)
• Female partner not of child-bearing (defined in Inclusion #4)
• Sexual abstinence, defined as refraining from heterosexual intercourse

If you have previously submitted an application, call 417-831-2048 to enroll. Or click on the button below to submit your application now.

Apply Online Now

Signup for our newsletter!

"*" indicates required fields

This field is for validation purposes and should be left unchanged.

Important Links

  • Home
  • About
  • Our Studies
  • Ongoing Studies
  • Enroll
  • FAQs
  • Referral Program
  • Join Our Team
  • Blog
  • Contact
  • Privacy Policy

QPS Missouri

QPS Study Campus
1820 W. Mount Vernon Street
Springfield, MO 65802

QPS Screening and Recruitment Center
2025 W. Sunshine Street, L-109
Springfield, MO 65807

Hours of Operation:
Monday – Friday
8 a.m. – 5 p.m.

Call us at 417.831.2048

Employees

  • Employee Portal

qps bird logo outline

Copyright © 2025 QPS Missouri | All Rights Reserved